SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lockmer Sandra)
 

Sökning: WFRF:(Lockmer Sandra) > Survival by First-l...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004674naa a2200469 4500
001oai:DiVA.org:uu-498884
003SwePub
008230323s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:152008248
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4988842 URI
0247 a https://doi.org/10.1097/HS9.00000000000008382 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1520082482 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Weibull, Caroline E.u Karolinska Institutet4 aut
2451 0a Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients :b A National Population-based Study in Sweden
264 1b Wolters Kluwer,c 2023
338 a electronic2 rdacarrier
520 a In follicular lymphoma (FL), progression of disease <= 24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national population-based setting. We identified 948 stage II-IV indolent FL patients in the Swedish Lymphoma Register diagnosed 2007-2014 who received first-line systemic therapy, followed through 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by first POD at any time during follow-up using Cox regression. OS was predicted by POD using an illness-death model. During a median follow-up of 6.1 years (IQR: 3.5-8.4), 414 patients experienced POD (44%), of which 270 (65%) occurred <= 24 months. POD was represented by a transformation in 15% of cases. Compared to progression-free patients, POD increased all-cause mortality across treatments, but less so among patients treated with rituximab(R)-single (HR = 4.54, 95% CI: 2.76-7.47) than R-chemotherapy (HR = 8.17, 95% CI: 6.09-10.94). The effect of POD was similar following R-CHOP (HR = 8.97, 95% CI: 6.14-13.10) and BR (HR = 10.29, 95% CI: 5.60-18.91). The negative impact of POD on survival remained for progressions up to 5 years after R-chemotherapy, but was restricted to 2 years after R-single. After R-chemotherapy, the 5-year OS conditional on POD occurring at 12, 24, and 60 months was 34%, 46%, and 57% respectively, versus 78%, 82%, and 83% if progression-free. To conclude, POD before but also beyond 24 months is associated with worse survival, illustrating the need for individualized management for optimal care of FL patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Wasterlid, Toveu Karolinska Institutet4 aut
7001 a Wahlin, Bjorn Engelbrektu Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.4 aut
7001 a Andersson, Per-Olau Sahlgrens Univ Hosp, Sect Hematol & Coagulat, Gothenburg, Sweden.4 aut
7001 a Ekberg, Sarau Karolinska Institutet4 aut
7001 a Lockmer, Sandrau Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.4 aut
7001 a Enblad, Gunillau Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)gunienbl
7001 a Crowther, Michael J.u Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Red Door Analyt, Stockholm, Sweden.4 aut
7001 a Kimby, Evau Karolinska Institutet4 aut
7001 a Smedby, Karin E.u Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.4 aut
7102 a Karolinska Institutetb Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.4 org
7730 t HemaSphered : Wolters Kluwerg 7:3q 7:3x 2572-9241
8564 u https://doi.org/10.1097/HS9.0000000000000838y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1745621/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498884
8564 8u https://doi.org/10.1097/HS9.0000000000000838
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:152008248

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy